Main Subject - Finance

Australian share trader, Joel Green said that his 137.4%* return from his share trading adventures woul

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

d have been unlikely 3 years ago.

"I did my stock market education training in July 2002. 3 months lat

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

er I had put together my first strategy," Joel said.

"The stock market can seem a gamble to many peopl

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

. People are wondering what to do in the current market downturn. Empower yourself with a strategy so y

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

ou know exactly what to do, whatever the market throws at you, before it is too late."

"Emotions must

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

e overcome in order for people to safely and consistently make the returns they are aiming for."

Three

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

approaches to trading are common:

1. Rely on other people's tips

2. Buy a bunch of shares and hope t

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

o get rich

3. Avoid the Stock Market altogether

"I took the first approach before I commenced my educ

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

tion. I was taught a new approach. I learned how to develop my own strategy with easy-to-follow rules

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

for buying, selling and managing risk. I had a system I could test before I spent any money to see if i

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

made the returns I wanted. If you had told me you could develop and test a strategy for the stock mark

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

et 3 years ago, I would have laughed at you."

"The best piece of advice I can offer, is to get a good

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

quality education. Learn how it works and do not take chances with your money."

"Avoid myths such as t

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

e belief you must stay away from the share market because prices can go down. This is nonsense! With an

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

education, you can learn techniques that people use daily to make money, even from falling share price

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

."

"Investors should consider developing their own trading approach to make their own investment decis

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

ions and control their own financial future, with their own money," according to Joel.

"I know this 13

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

7.4%* is hard to believe and it's true that not everyone can achieve this sort of result, but if you do

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

't get an education and develop your own system, and receive ongoing mentoring, you'll never know what

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

you can achieve," he said.

* Past performance is not a reliable indicator of future performance.

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

Tags

Links

Main Subject - 137% Return Seemed An Unlikely Result For Beginner Share Trader

Related Articles: